Killing of Borrelia burgdorferi by Antibody Elicited by OspA Vaccine Is Inefficient in the Absence of Complement
A Lyme disease vaccine, based on the Borrelia burgdorferi lipoprotein OspA, has recently undergone phase III trials in humans. The results of one of these trials indicate that vaccine efficacy positively correlates with anti-OspA antibody titer. Spirochete killing within the tick vector midgut, upon...
Enregistré dans:
| Publié dans: | Infect Immun |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society for Microbiology (ASM)
1999
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC96334/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9864253/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.67.1.443-445.1999 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|